AU2010326699B2 - Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor - Google Patents

Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor Download PDF

Info

Publication number
AU2010326699B2
AU2010326699B2 AU2010326699A AU2010326699A AU2010326699B2 AU 2010326699 B2 AU2010326699 B2 AU 2010326699B2 AU 2010326699 A AU2010326699 A AU 2010326699A AU 2010326699 A AU2010326699 A AU 2010326699A AU 2010326699 B2 AU2010326699 B2 AU 2010326699B2
Authority
AU
Australia
Prior art keywords
cladribine
hdaci
transdermal patch
transdermal
hypomethylating agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010326699A
Other languages
English (en)
Other versions
AU2010326699A1 (en
Inventor
Elliot M. Epner
Luke M. Vaughan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NIMBLE EPITECH LLC
Original Assignee
NIMBLE EPITECH LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NIMBLE EPITECH LLC filed Critical NIMBLE EPITECH LLC
Publication of AU2010326699A1 publication Critical patent/AU2010326699A1/en
Application granted granted Critical
Publication of AU2010326699B2 publication Critical patent/AU2010326699B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2010326699A 2009-12-02 2010-04-30 Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor Ceased AU2010326699B2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US28330509P 2009-12-02 2009-12-02
US61/283,305 2009-12-02
US30195610P 2010-02-05 2010-02-05
US61/301,956 2010-02-05
US32008310P 2010-04-01 2010-04-01
US61/320,083 2010-04-01
US12/769,913 2010-04-29
US12/769,913 US8491927B2 (en) 2009-12-02 2010-04-29 Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
PCT/US2010/001287 WO2011068522A1 (en) 2009-12-02 2010-04-30 Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor

Publications (2)

Publication Number Publication Date
AU2010326699A1 AU2010326699A1 (en) 2012-07-19
AU2010326699B2 true AU2010326699B2 (en) 2016-01-07

Family

ID=44069079

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010326699A Ceased AU2010326699B2 (en) 2009-12-02 2010-04-30 Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor

Country Status (9)

Country Link
US (3) US8491927B2 (enExample)
EP (1) EP2506814A4 (enExample)
JP (1) JP6002040B2 (enExample)
KR (1) KR20120127580A (enExample)
CN (1) CN102711686A (enExample)
AU (1) AU2010326699B2 (enExample)
CA (1) CA2782205A1 (enExample)
MX (1) MX2012006128A (enExample)
WO (1) WO2011068522A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8491927B2 (en) * 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
CA2868302A1 (en) 2012-03-23 2013-09-26 Dennis M. Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
WO2013162054A1 (ja) * 2012-04-24 2013-10-31 公立大学法人首都大学東京 クロマチン構造を制御する組成物
JP6243102B2 (ja) * 2012-05-01 2017-12-06 株式会社ジェムインターナショナル 貼付剤
FR2993461B1 (fr) * 2012-07-19 2014-08-08 Genethon Utilisation de composes modifiant l'epigenome pour le traitement des maladies genetiques musculaires liees a une anomalie de conformation proteique
WO2014022524A1 (en) * 2012-07-31 2014-02-06 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
US20140142522A1 (en) * 2012-11-16 2014-05-22 NU Technology, LLC Moist dressing with honeycomb pattern and drain channels
AU2015289922A1 (en) * 2014-07-15 2017-02-16 The Johns Hopkins University Suppression of myeloid derived suppressor cells and immune checkpoint blockade
US9962340B2 (en) 2015-06-09 2018-05-08 Life Tech Global, Llc Device and method for the transdermal delivery of cannabidiol
US10272125B2 (en) * 2015-09-14 2019-04-30 Life Tech Global, Llc Transdermal delivery of cannabidiol with other active moieties including cannabinoids
GB2567362B (en) 2016-07-15 2022-04-20 Nantkwest Inc HDAC inhibitors for use with NK cell based therapies
US20180353446A1 (en) * 2017-06-07 2018-12-13 Ranedis Pharmaceuticals, Llc Compositions and methods of treating and/or preventing cancer
BR112021024073A2 (pt) 2019-05-31 2022-04-26 Viracta Subsidiary Inc Métodos de tratamento de cânceres associados a um vírus com inibidores de histona desacetilase
JP2022552642A (ja) * 2019-10-07 2022-12-19 ヴィラクタ サブシディアリー，インク． 副作用が軽減されたｈｄａｃ治療の調剤
US20220087948A1 (en) * 2020-09-18 2022-03-24 Nanovibronix, Inc. Transdermal patch of a portable ultrasound-generating system for improved delivery of therapeutic agents and associated methods of treatment

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040081685A1 (en) * 2000-11-16 2004-04-29 Euro-Celtique, S.A. Titratable dosage transdermal delivery system
US20050255150A1 (en) * 2004-04-26 2005-11-17 Cassel Douglas R Wound treatment patch for alleviating pain
US20070281934A1 (en) * 2006-03-16 2007-12-06 Pharmacyclics, Inc. Indole derivatives as inhibitors of histone deacetylase

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
ATE12348T1 (de) 1980-11-10 1985-04-15 Gersonde Klaus Prof Dr Verfahren zur herstellung von lipid-vesikeln durch ultraschallbehandlung, anwendung des verfahrens und vorrichtung zur durchfuehrung des verfahrens.
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
JPS62126123A (ja) 1985-11-28 1987-06-08 Shigeki Suzuki バルプロ酸の経皮吸収方法
EP0601058A4 (en) 1991-08-27 1995-05-31 Cygnus Therapeutic Systems TRANSDERMAL FORMULATIONS FOR PRRAZOSINE ADMINISTRATION.
CA2217014A1 (en) 1995-04-07 1996-10-10 Novartis Ag Iontophoretic transdermal system for the administration of at least two substances
US5736154A (en) 1996-03-11 1998-04-07 Fuisz Technologies Ltd. Transdermal delivery system
FR2749514B1 (fr) 1996-06-11 1998-08-07 Hoechst Marion Roussel Systemes transdermiques renfermant 2 principes actifs dans des compartiments separes, leur procede de preparation et leur application comme medicament
US6479074B2 (en) * 1996-10-24 2002-11-12 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
AU5495798A (en) * 1997-01-16 1998-08-07 Sekisui Chemical Co., Ltd. External preparations for percutaneous absorption
MXPA00012767A (es) 1998-06-29 2002-08-09 Pharmaceuticals Applic Asociat Metodos y composiciones transdermicas para el alivio del dolor.
US6599912B1 (en) 1999-06-03 2003-07-29 Jessie L. -S. Au Methods and compositions for modulating cell proliferation and cell death
IL138686A0 (en) 1999-10-01 2001-10-31 Pfizer Prod Inc α- SULFONYLAMINO HYDROXAMIC ACID INHIBITORS OF MATRIX METALLOPROTEINASES FOR THE TREATMENT OF PERIPHERAL OR CENTRAL NERVOUS SYSTEM DISORDERS
AU2001277887B2 (en) 2000-07-14 2006-09-14 Transform Pharmaceuticals, Inc. System and method for optimizing tissue barrier transfer of compounds
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
EP1293205A1 (en) 2001-09-18 2003-03-19 G2M Cancer Drugs AG Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease
MXPA04005361A (es) 2001-12-13 2004-09-27 Vital Health Sciences Pyt Ltd Transporte transdermico de compuestos.
US6841565B1 (en) * 2002-03-29 2005-01-11 The Ohio State University Treatment of patients with chronic lymphocytic leukemia
EP1638963B1 (en) 2003-05-20 2009-09-09 Novartis AG N-acyl nitrogen heterocycles as ligands of peroxisome proliferator-activated receptors
EP1646628A1 (en) 2003-07-08 2006-04-19 Novartis AG Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds
US20050059682A1 (en) 2003-09-12 2005-03-17 Supergen, Inc., A Delaware Corporation Compositions and methods for treatment of cancer
US8012944B2 (en) * 2003-10-30 2011-09-06 Pharmascience Inc. Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
RU2413716C2 (ru) 2003-11-26 2011-03-10 Новартис Аг АМИДЫ δ-АМИНО-γ-ГИДРОКСИ-ω-АРИЛАЛКАНОВОЙ КИСЛОТЫ
WO2005065668A2 (en) 2003-12-29 2005-07-21 Qlt Usa, Inc. Topical compositions comprising halo-deoxyadenosines for treatment of skin disorders
KR100602434B1 (ko) 2004-09-10 2006-07-19 최상식 복수 개의 단위 구획을 포함하는 약물의 경피 투여용 패치
WO2007024574A2 (en) 2005-08-19 2007-03-01 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Topical formulations of histone deacetylase inhibitors and methods of using the same
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
WO2007041584A2 (en) * 2005-10-03 2007-04-12 Combinatorx, Incorporated Implantable sensors, implantable pumps, and anti-scarring drug combinations
BRPI0520686A2 (pt) 2005-11-16 2009-05-19 Univ Mexico Nacional Autonoma uso de agentes modificantes de transcriptoma associado a quimioterapia ou radioterapia contra o cáncer
ES2548240T3 (es) 2005-12-01 2015-10-15 Pronai Therapeutics, Inc. Terapias para el cáncer y composiciones farmacéuticas usadas en las mismas
US20110077215A1 (en) 2005-12-07 2011-03-31 The University Of Utah Research Foundation DNA Methylation As A Target For Diagnosis And Treatment Of Chronic Lymphocytic Leukema (CLL)
US8058258B2 (en) 2006-03-02 2011-11-15 Agency For Science, Technology And Research Methods for cancer therapy and stem cell modulation
US8585753B2 (en) * 2006-03-04 2013-11-19 John James Scanlon Fibrillated biodegradable prosthesis
ES2444890T3 (es) 2006-03-31 2014-02-27 Erasmus University Medical Center Rotterdam Nueva composición para el control del crecimiento tumoral
AU2007247571A1 (en) * 2006-05-05 2007-11-15 Coloplast A/S A pressure sensitive adhesive composition comprising cross-linked polyalkylene oxide and water absorbent hydrophilic agents
US20110104177A1 (en) 2006-12-28 2011-05-05 The Johns Hopkins University Histone deacetylase inhibitors, combination therapies and methods of use
EP2491923A3 (en) 2007-02-15 2012-12-26 Novartis AG Combinations of therapeutic agents for treating cancer
WO2008116163A1 (en) 2007-03-22 2008-09-25 Oregon Health & Science University Therapeutic drug combinations for treatment of b-cell malignancies
US8163279B2 (en) 2007-04-13 2012-04-24 Stemline Therapeutics, Inc. IL3Rα antibody conjugates and uses thereof
US20090025274A1 (en) 2007-07-23 2009-01-29 Tim Lail Animal trap
JP2011500086A (ja) 2007-10-22 2011-01-06 シェーリング コーポレイション 完全ヒト抗ｖｅｇｆ抗体および使用方法
WO2009067453A1 (en) * 2007-11-19 2009-05-28 Syndax Pharmaceuticals, Inc. Combinations of hdac inhibitors and proteasome inhibitors
US20110053991A1 (en) * 2007-11-19 2011-03-03 Gore Lia Treatment of Histone Deacetylase Mediated Disorders
PT2695609T (pt) 2008-05-15 2020-03-02 Celgene Corp Formulações orais de análogos da citidina e métodos de utilização dos mesmos
WO2009155477A1 (en) 2008-06-19 2009-12-23 The Trustees Of The University Of Pennsylvania Inducible regulatory t-cell generation for hematopoietic transplants
WO2010020787A1 (en) 2008-08-22 2010-02-25 Oncomethylome Sciences Sa Diagnosis and treatment of tumours
US9028833B2 (en) * 2012-12-13 2015-05-12 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US20100298255A1 (en) * 2009-05-19 2010-11-25 Vivia Biotech S.L. Methods for providing personalized medicine test ex vivo for hematological neoplasms
US8491927B2 (en) * 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
JP5548470B2 (ja) * 2010-02-16 2014-07-16 日本碍子株式会社 ハニカム触媒体
US20110245154A1 (en) * 2010-03-11 2011-10-06 Hemaquest Pharmaceuticals, Inc. Methods and Compositions for Treating Viral or Virally-Induced Conditions
EP2382993A1 (en) * 2010-04-19 2011-11-02 KTB Tumorforschungsgesellschaft mbH Combination of drugs with protein-binding prodrugs
WO2012044936A1 (en) * 2010-09-30 2012-04-05 Portola Pharmaceuticals, Inc. Combination therapy with 4-(3-(2h-1,2,3-triazol-2-yl)phenylamino)-2-((1r,2s)-2-aminocyclohexylamino)pyrimidine-5-carboxamide
SI2786756T1 (sl) * 2010-11-12 2020-07-31 Pharma Mar S.A. Kombinirana terapija z zaviralci topizomeraze
US20130004481A1 (en) * 2011-01-12 2013-01-03 Boehringer Ingelheim International Gmbh Anticancer therapy
TW201300385A (zh) * 2011-04-08 2013-01-01 Afraxis Inc 用於治療ｃｎｓ病症和癌症的８－乙基－６－（芳基）吡啶并［２，３－ｄ］嘧啶－７（８ｈ）－酮
WO2012142480A1 (en) * 2011-04-14 2012-10-18 Beth Israel Deaconess Medical Center, Inc. Chimeric rna oligonucleotides and uses thereof
US20140170148A1 (en) * 2011-04-20 2014-06-19 Genmab A/S Bispecific antibodies against her2
US9896730B2 (en) * 2011-04-25 2018-02-20 OSI Pharmaceuticals, LLC Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
MX2014000130A (es) * 2011-06-28 2014-05-01 Pharmacyclics Inc Procedimientos y composiciones para la inhibicion de resorcion osea.
BR112014010417A2 (pt) * 2011-11-01 2014-11-18 Celgene Corp Métodos para o tratamento de cânceres com o uso de formulações orais de análogos de citidina
AU2012330498A1 (en) * 2011-12-09 2013-06-27 Afraxis Holdings, Inc. PAK inhibitors for the treatment of cancer
EP2854811A1 (en) * 2012-05-31 2015-04-08 Amgen Inc. Use of amg 900 for the treatment of cancer
KR20150015021A (ko) * 2012-06-04 2015-02-09 파마시클릭스, 인코포레이티드 브루톤 타이로신 키나아제 저해제의 결정 형태
WO2014009319A1 (en) * 2012-07-11 2014-01-16 Boehringer Ingelheim International Gmbh Indolinone derivatives anticancer compounds
WO2014009318A1 (en) * 2012-07-11 2014-01-16 Boehringer Ingelheim International Gmbh 3-{3-[1 -(4-dimethylaminomethyl-phenylamino)-1 -phenyl-meth-(z)-ylidene]-2-oxo-2,3-dihydro-1 h-indol-6-yll-propynoic acid ethylamide and its use in the treatment of cancer
PE20150617A1 (es) * 2012-08-09 2015-05-21 Celgene Corp Formas solidas de 3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona o un estereoisomero del mismo, de sus sales, y composiciones que comprenden las mismas
PL2882442T3 (pl) * 2012-08-09 2021-12-13 Celgene Corporation Sposoby leczenia nowotworów z wykorzystaniem 3-(4-((4-(morfolinometylo)benzylo)oksy)-1-oksoizoindolin-2-ylo)piperydyno-2,6-dionu
US9682143B2 (en) * 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
US9315567B2 (en) * 2012-08-14 2016-04-19 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
US20140120083A1 (en) * 2012-11-01 2014-05-01 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040081685A1 (en) * 2000-11-16 2004-04-29 Euro-Celtique, S.A. Titratable dosage transdermal delivery system
US20050255150A1 (en) * 2004-04-26 2005-11-17 Cassel Douglas R Wound treatment patch for alleviating pain
US20070281934A1 (en) * 2006-03-16 2007-12-06 Pharmacyclics, Inc. Indole derivatives as inhibitors of histone deacetylase

Also Published As

Publication number Publication date
EP2506814A4 (en) 2013-05-22
CA2782205A1 (en) 2011-06-09
EP2506814A1 (en) 2012-10-10
JP6002040B2 (ja) 2016-10-05
US20120310183A1 (en) 2012-12-06
JP2013512898A (ja) 2013-04-18
AU2010326699A1 (en) 2012-07-19
US8491927B2 (en) 2013-07-23
US10434090B2 (en) 2019-10-08
US20110129521A1 (en) 2011-06-02
WO2011068522A1 (en) 2011-06-09
US20200222379A1 (en) 2020-07-16
MX2012006128A (es) 2012-09-07
CN102711686A (zh) 2012-10-03
KR20120127580A (ko) 2012-11-22

Similar Documents

Publication Publication Date Title
AU2010326699B2 (en) Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
CA2636527C (en) Viral hepatitis treatment
KR102452022B1 (ko) 항종양 알칼로이드를 이용한 병용요법
ES2705529T3 (es) Tratamiento combinatorio del cáncer
JP7047148B2 (ja) 骨髄腫を治療するためのセルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ）
RU2008141763A (ru) Лечение рака молочной железы, негативного по трем рецепторам
JP2013512898A5 (enExample)
CA3224544A1 (en) Treatment of immune-related disorders, kidney disorders, liver disorders, hemolytic disorders, and oxidative stress-associated disorders using nrh, narh and reduced derivatives thereof
WO2014022524A1 (en) Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
WO2016053989A2 (en) Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
KR20120104574A (ko) 티보자닙과 템시롤리무스의 조합물
US20210315898A1 (en) Combination therapy for treating cancer
CN116509865B (zh) 硝酮类化合物在制备预防或治疗骨髓抑制药物中的应用
KR20210039413A (ko) 암의 치료를 위한 병용 요법
RU2482855C2 (ru) Противоопухолевое средство, включающее производное цитидина и карбоплатин
CZ20021562A3 (cs) Pouľití treosulfanu jako prostředku upravujícího předoperační stav pacienta před transplantací kostní dřeně nebo transplantací krevních kmenových buněk
Li et al. Functional role of DNMT1 in the anti-leukemic effects of hypomethylating agents in AML cells
KR20050042225A (ko) 아데노신 ａ1/ａ2 효능제 및 나트륨 수소 교환 억제제를포함하는 약제학적 조성물
Chatterji et al. Microtubules as Anti-Cancer Drug Targets
HK1186130A (en) Combinatory cancer treatment
CA3154497A1 (en) Combination therapy for treating a hematological malignancy
Bouscary et al. P-110 Thalidomide for the treatmentof low risk myelodysplasia: The ThaI-SMD-200 trial
ES2594499A1 (es) Complejos de Rutenio para el tratamiento del cáncer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired